Document:

EX-10.p

 *Confidential Treatment Requested 

Exhibit 10p 

Bristol-Myers Squibb Company 
 345 Park Avenue 
 New York, NY 10154 

January 1, 2013 
 Sanofi

 54, rue la Boétie 
 75008
Paris, FRANCE 
 Ladies and Gentlemen: 
 Reference is hereby made to that certain Master Restructuring Agreement, dated as of September 27, 2012 (the “Master Restructuring Agreement”), by and between Bristol-Myers Squibb
Company, a Delaware corporation (“BMS”), and Sanofi, a société anonyme organized under the laws of the French Republic (“Sanofi”). Pursuant to Section 12.8 of the Master Restructuring
Agreement, BMS and Sanofi intend to modify, amend or otherwise supplement the Master Restructuring Agreement as set forth herein. This letter shall be construed as an integral part thereof. Capitalized terms used but not defined herein shall have
the meanings assigned to them in the Master Restructuring Agreement. 
 In consideration of the mutual covenants and the terms
and conditions contained herein, and for good, valuable and binding consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 

1. Exhibit A attached hereto contains a description of the status, as of December 19, 2012, of the transfer of the marketing
authorizations for the Products currently held by BMS or its Affiliates that are set forth on Schedule 5.1(a) of the Master Restructuring Agreement and as amended hereto, the remaining steps required to complete the transfer of such marketing
authorizations and the timeline for implementing such steps. 
 2. On the Initial Closing Date, Sanofi SA, a Swiss Affiliate of
Sanofi, shall purchase the [*] shares of Sanofi/Bristol-Myers Squibb SA held by Bristol-Myers Squibb AG for a purchase price of [*] (“Swiss Purchase Price”) in accordance with the agreement substantially in the form attached hereto
as Exhibit B. The Swiss Purchase Price shall be deducted from the remuneration to be made by JVA to BMS in accordance with the terms and provisions of the Master Restructuring Agreement, Amended and Restated Territory A Clopidogrel License,
the Amended and Restated Territory A Irbesartan License, and the Amended and Restated Territory A Know-How License. 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 3. Section 3.3(a) of the Master Restructuring Agreement is hereby deleted in its
entirety and replaced with the following: 
 “(a) Each of the Parties shall (i) cause their Affiliate(s) and/or their
partnerships referenced herein, as applicable, to execute supply or tolling agreements in substantially the forms attached hereto as Exhibits 3.3(a)[1] to [5] as of the Initial Closing Date and (ii) agree in good faith to amend
the existing quality agreements prior to [*] to reflect changes in the underlying responsibilities of the Parties and their Affiliates (“Quality Agreement Amendments” and, together with the agreements referenced in clause
(i) above, the “Supply Agreements”), in order to memorialize the supply or tolling arrangements for: (A) manufacturing finished Product tablets and packaging for Clopidogrel Products in the U.S.; (B) packaging and
releasing Irbesartan Products and Clopidogrel Products for Mexico, Argentina and Colombia; and (C) manufacturing Irbesartan API and Irbesartan intermediates for Irbesartan Products throughout the world (other than in Japan) as described in this
Article III.” 
 4. Section 2.2 of the Master Restructuring Agreement is hereby amended as follows to reflect that
USIrbeJV shall use commercially reasonable efforts to sell the inventory owned by USIrbeJV to wholesalers prior to the Initial Closing Date1: 
 (a) by deleting the first sentence of subsection (b) in its entirety and replacing it with the following: 
 “BMS’s overall remuneration for the sale of its interest in USIrbeJV, forbearance of certain rights under the Alliance Agreements relating to USIrbeJV, and continuing use of the BMS Brands in
accordance with Article VI hereof, shall consist of the payment (on a quarterly basis and payable in the following quarter) of the applicable percentage (as set forth in Table 2.2(b) below and subject to the provisions of
Sections 2.2(c) and (d) herein) of IFRS Net Sales in the U.S. of Irbesartan Products between the Initial Closing Date and the Termination Date, less [*]. If the net first quarterly payment is [*], then the balance of
such amount shall be [*] from succeeding quarterly payments until [*], at which time, no [*] shall apply to such quarterly payments.” 
 (b) by deleting subsection (e) in its entirety and replacing it with the following: 
 “(e) [Intentionally Omitted]” 
 5. The Parties shall cooperate in good
faith to agree upon an equitable allocation of liabilities between the Parties and their respective Affiliates in each of the Co-Marketing countries with respect to [*] for (a) Products sold by BMS or its Affiliates prior to the Initial Closing
Date and (b) Products sold on or after the Initial Closing Date by Sanofi or its Affiliates from Transferred Inventory. In all Co-Marketing countries, the principles set forth in the applicable termination agreements for the Co-Marketing
distribution agreements shall apply and shall be supplemented with the following provisions, on a country-by-country basis, when the liability for [*] cannot be clearly allocated to a specific party: 

 

	 	•	 	 Germany: BMS’s Affiliate in Germany shall manage and process, at its own cost and expense, [*] from [*] until [*]. After [*], Sanofi shall
manage and process, at its own cost and expense, [*] of [*]. 

  

	1 	In the event that there are products remaining in the inventory held by USIrbeJV as of the Initial Closing Date, such inventory shall be destroyed after the Initial
Closing Date. Costs of such destruction shall be equally shared between Sanofi and BMS. 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 BMS shall manage and assume liability for [*] of [*] until [*]. After [*], Sanofi shall
manage and assume liability for [*] of [*]. 
  

	 	•	 	 Italy: BMS’s Affiliate in Italy shall manage and process, at its own cost and expense, [*] of [*] through [*]. Sanofi shall manage and
process, at its own cost and expense, [*] of such [*] from and after [*]. 

  

	 	•	 	 Australia: No need for specific arrangements. 

  

	 	•	 	 Argentina: BMS’s Affiliate in Argentina shall manage and process, at its own cost and expense, [*] of [*] through [*]. Sanofi shall manage
and process, at its own cost and expense, [*] of such [*] from and after [*]. 

  

	 	•	 	 Greece: Sanofi shall manage and process, at its own cost and expense, [*] of [*] as of the Initial Closing Date. 

 

	 	•	 	 Spain: When the Sanofi Affiliate or the BMS Affiliate has sold [*]% or more of the Products corresponding to a batch of [*], then [*]% of the
[*] corresponding to such batch shall be managed and processed by the Sanofi Affiliate or BMS Affiliate, respectively (such party, the “Marketing Party”), that sold such batch, at its own cost and expense. All costs of [*] for the
[*] shall be the sole responsibility of the Marketing Party. If either the Sanofi Affiliate or the BMS Affiliate receives [*] that are part of the batches sold by the Marketing Party, the party that received such [*] shall deliver such [*] to the
Marketing Party, together with a copy of any necessary documents related to such [*]. Any costs for transferring such [*] to the Marketing Party shall be assumed by the Marketing Party. 

 

	 	•	 	 Mexico: Sanofi shall manage and process, at its own cost and expense, [*] of [*] as of the Initial Closing Date. 

For further clarity, notwithstanding Section 5.1 of the transition distribution agreements to be executed by the Parties’ respective Affiliates
and effective as of the Initial Closing Date, Sanofi shall be responsible for the costs of [*] sold on or after the Initial Closing Date pursuant to a transition distribution agreement if the recall is caused by the fault or negligence of Sanofi or
its Affiliates. 
 In Co-Promotion countries, other than Canada, the management of returns shall be managed by the Managing Partner in
accordance with Section 5 of the Agreed Principles for the Winding-Up of Local Partnerships, which is attached as Exhibit 2.1(i) to the Master Restructuring Agreement. 
 Subject to Paragraph 9 below, in Canada, Section 5 of the Agreed Principles for the Winding-Up of Local Partnerships is amended to the extent necessary to reflect Exhibit C attached hereto
when the liability for returns, rebates, credits or chargebacks cannot be allocated to a Product sold by the local Canadian partnership prior to the Initial Closing Date or by local Sanofi Affiliate after the Initial Closing Date. 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 6. The Parties acknowledge that Sanofi and its Affiliates shall have the exclusive right to
distribute the Products in the relevant Territory as of the Initial Closing Date. In those Co-Marketing countries where the applicable local BMS Affiliates and the applicable local Sanofi Affiliates enter into transition distribution agreements
effective as of the Initial Closing Date, Sanofi shall not enter into any new, or amend any existing, agreements or arrangements, including tenders for supply contracts, after the Initial Closing Date where such agreement or arrangement relate to a
Products that is subject to such transitory distribution agreement and would create an obligation (including, without limitation, as a guarantor) or administrative or reporting burden on the part of BMS or its local Affiliate after the Initial
Closing Date, without BMS’s prior written consent. If BMS consents to the entry into such agreement or arrangement, then Sanofi shall indemnify, defend and hold harmless BMS and its Affiliates from any [*] and [*]; provided, that BMS provides
notice to Sanofi and allows Sanofi to control the defense and settlement of any third party claims for damages in a manner consistent with that described for cases where BMS controls the defense and settlement of the German Actions as provided in
paragraph 7(i) below. For clarity, the preceding sentence shall not apply to claims of personal injury or death based on product liability or similar claims, the indemnification and liability for which shall remain governed by the Master
Restructuring Agreement. 
 7. For purposes of clarity: 
 (i) Sanofi acknowledges that, under the terms of the Master Restructuring Agreement, (a) [*] may commence actions in [*] after the Initial Closing Date to [*] the [*] that [*] on [*] prior to the
Initial Closing Date (the [*]), (b) [*] shall not [*], and (c) [*] shall belong to [*] and [*]. In addition to any rights to indemnification that [*] may have under the applicable Alliance Support Agreement in accordance with
Section 9.1(a) of the Master Restructuring Agreement, [*] shall indemnify, defend and hold harmless [*] from any [*] and [*], against whom [*] and are [*]; provided that (a) a [*], must in each case, [*]; and (b) [*] provides prompt
notice to [*] and not [*], and [*] shall have the right to [*]. In addition, [*] shall reimburse [*] for any [*] and [*]. 
 (ii)
With respect to: 
 (a) any lawsuits brought in countries in [*], after the Initial Closing Date relating to [*], prior to the
Initial Closing Date, [*] and/or 
 (b) any lawsuits brought by the [*] relating to [*], prior to the Initial Closing Date, of
[*], 
 such litigation shall be governed by section 7.2(b) of the Master Restructuring Agreement, provided, that in any such
litigation in which BMS participates, (i) any damages or awards from such proceedings will be determined on a [*] basis (as opposed to applying the [*] in [*] of the applicable Alliance Support Agreement) and (ii) all key litigation
decisions and strategies of BMS and Sanofi (or of the BMS Partner and the Sanofi Partner if a Partnership is involved) shall be mutually agreed by the Parties. 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 8. BMS shall assign to Sanofi, as of the Initial Closing Date, those tenders in [*] and [*]
listed in Exhibit D for which BMS has obtained, on or prior to the Initial Closing Date, the third party consents necessary for the assignment of such tender(s) to Sanofi. Promptly after the Initial Closing Date, BMS shall provide to Sanofi a
written list of such assigned tenders, together with a copy of the consent letter obtained by BMS for the assignment of the tender(s). 
 For those tenders in [*] and [*], which third party consent for the assignment to Sanofi has not been obtained by BMS as of the Initial Closing Date, BMS shall continue to use commercial reasonably
efforts to obtain such consent as soon as reasonably practicable from and after the Initial Closing Date until [*]. Sanofi shall assume all tenders for which BMS has obtained, on or prior to [*], the consent to assignment to Sanofi. All tenders for
which BMS has not obtained the consent to the assignment to Sanofi on or prior [*] shall not be assigned to Sanofi and shall remain with BMS (each a “Non-Assigned Tender” and, collectively, the “Non-Assigned
Tenders”). 
 For those tenders in [*] which have been entered into by [*] under contracts with [*] and [*], [*] shall
use its commercially reasonable efforts to terminate its agreement with [*] with respect to the Irbesartan Products and Clopidogrel Products to be supplied by [*] under said two contracts so that [*] may enter into a new agreement with [*] for such
supply. If [*] is unable to terminate its agreement with [*] (the [*]), such agreement shall remain with [*]. 
 BMS shall be
solely liable for and shall indemnify, defend and hold harmless Sanofi and its Affiliates from any [*] and [*]; provided, that Sanofi provides notice to BMS and allows BMS to control the defense and settlement thereof in the same manner as provided
in paragraph 7(i) above for a German Action. For clarity, the preceding sentence shall not apply to claims of personal injury or death based on product liability or similar claims, the indemnification and liability for which shall remain governed by
the Master Restructuring Agreement. 
 Notwithstanding the foregoing, [*] shall make their commercially reasonable efforts to
supply Products that may be ordered from [*] by a Tender Contractee under the Non-Assigned Tenders and the [*] in accordance with the terms of the applicable tender (as communicated by [*] to [*]), if in the reasonable opinion of [*], such direct
supplies by [*] are legally feasible. If a Tender Contractee under the Non-Assigned Tenders and the [*] refuses to purchase a Product directly from [*] and requires that [*] supply such Product, then [*] will endeavor in good faith to find a
mutually acceptable, lawful solution that will allow for such supply by [*]. 
 9. Should [*] the [*] for a [*] after the
Initial Closing Date in a manner that results in [*]. Specifically, [*] shall apply the [*] first to their [*] and only if [*] would the [*] assume responsibility for the [*]. The information and calculation of the [*] shall be shared with [*] and
agreed to [*] prior to [*]. New [*] and [*] information shall be [*] and adjusted accordingly. 
 10. The “Responsible
Person” nominated for the Australia Pharmaceutical Benefits Scheme (“PBS”) items has obligations regarding disclosure of information according to 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 
applicable Australian legislation. In the event that the transfer from BMS to Sanofi of the “Responsible Person” for the Pharmaceutical Benefits Schedule listing of relevant brands
occurs after the Initial Closing Date, the Parties agree to the following approach to fulfil these obligations: 
  

	 	•	 	 BMS shall give authority to an authorized person at Sanofi to disclose information for the relevant brands (Iscover® and DuoCover®) for the
period from the Initial Closing Date until the date on which Sanofi becomes the “Responsible Person” (the “PBS Transition Period”), given that Sanofi shall have the required sales data, but BMS will have been the
Responsible Person for that period under the PBS. After the PBS Transition Period, Sanofi shall make all required disclosures under the PBS thereafter. 

 

	 	•	 	 Sanofi shall give authority to an authorized person at BMS to disclose, as and when required by law, with respect to sales during the period from [*]
through [*], such information and sales data that is required from the Responsible Person during such period, given that BMS shall have the required sales data. 

 

	 	•	 	 Copies of the authorities for disclosure shall be provided to the Department of Health and Ageing before the transition date.

 11. Schedule 2.10 (Inventory Purchase) to the Master Restructuring Agreement is hereby replaced in
its entirety with the Schedule 2.10 attached hereto. 
 12. Schedule 4.2(b) (Assigned Contracts) to the Master
Restructuring Agreement is hereby replaced in its entirety with the Schedule 4.2(b) attached hereto. To the extent that any required consent for the assignment of an Assigned Contract has not been received as of the Initial Closing Date, BMS
shall use commercially reasonable efforts to obtain such required consent and BMS and Sanofi shall work together to negotiate in good faith a commercially reasonable and mutually agreeable arrangement under which Sanofi would obtain the benefits and
assume the obligations thereunder, or under which BMS would enforce for the benefit of Sanofi, with Sanofi assuming BMS’s obligations, any and all rights of BMS against a third party thereto. 

13. Schedule 5.1(a) (Marketing Authorizations) to the Master Restructuring Agreement is hereby amended to reflect that the
Duocover marketing authorization in Mexico that had originally been identified as a marketing authorization to be withdrawn will instead be transferred to the Sanofi Affiliate in Mexico. 

14. Schedule 7.2(b) (Intellectual Property Actions) to the Master Restructuring Agreement is hereby replaced in its entirety with
the Schedule 7.2(b) attached hereto. 
 15. Schedule 9.1 (Pending Claims) to the Master Restructuring Agreement is
hereby replaced in its entirety with the Schedule 9.1 attached hereto. 
 16. Except as expressly modified herein,
the Master Restructuring Agreement, including the exhibits schedules thereto, together with the other instruments referred to therein, including the Settlement Agreement, the Alliance Agreements and the Closing Date Agreements, is unchanged and
remains in full force and effect. In the event of a conflict between the terms of the Master Restructuring Agreement and the terms of this letter agreement, the terms of this letter agreement shall govern and control. 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 17. This letter agreement shall be governed by and construed in accordance with the laws of
the State of New York applicable to contracts executed and performed entirely in that state, without regarding to any principles of conflicts of laws thereof. 
 18. This letter agreement may be executed in one or more counterparts (including by facsimile or email “PDF” transmission), and by the different Parties in separate counterparts, each of which
when executed shall be deemed to be an original but all of which when taken together shall constitute one and the same agreement. 
 [Remainder of Page Intentionally Left Blank] 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Please acknowledge where indicated below that the foregoing represents your understanding
and agreement with respect to the matters described in this letter agreement. 
  

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	 /s/ Charles Bancroft

	Name:	 	Charles Bancroft
	Title:	 	Executive VP & Chief Financial Officer

 Acknowledged and Agreed: 
  

			
	SANOFI
		
	By:	 	 /s/ Boisson Gilles

	Name:	 	Boisson Gilles
	Title:	 	Authorized Representative

 [Signature Page to Side Letter] 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 [*][NOTE: TABLE CONTENT IS OMITTED.] 

SCHEDULE 2.10 
 INVENTORY PURCHASE 
 Transferred Inventory – Territories

 PART A 
  

																					
	 Countries 
Products
	  	 Products
	  	 SKU
	  	 Estimated

Future
Sales (in unit)
	  	 Estimated
Transferred
Inventory as
of
Initial
Closing Date
(in units)
	  	 Estimated Unit
Cost

in local
currency
(before unit cost
mark-up

percentage)
	  	 Unit Cost

Mark-up

percentage
	  	
Estimated Unit
Cost
in local currency
(after unit cost
mark-
up 
percentage)
	  	 Selling
Companies
	  	 Seller’s
Premises
	  	 Purchasing
Companies

	MEXICO Plant 1622	  		  		  		  		  		  		  		  	 Bristol-Myers

Squibb de

Mexico, S. de
 R.L. de C.V.
	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL MEXICO Plant
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	MEXICO Market 1624	  		  		  		  		  		  		  		  	 Bristol-Myers
 Squibb de
 Mexico, S. de

R.L. de C.V.
	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL MEXICO Market
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

																					
	 ARGENTINA
 1744
	  		  		  		  		  		  		  		  	 Bristol-Myers
 Squibb
 Argentina

S. R. L
	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
	  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL ARGENTINA
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	CANADA	  		  		  		  		  		  		  		  	 Bristol-Myers
 Squibb Canada
 Co.
	  		  	
	1728	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL CANADA
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	US	  		  		  		  		  		  		  		  	 Bristol-Myers Squibb Sanofi-

Synthelabo

Partnership
	  		  	
	1658	  		  		  		  		  		  		  		  	  		  	
	Bulk 1248	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL US
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	PUERTO RICO	  		  		  		  		  		  		  		  	 Bristol-Myers
 Squibb Puerto
 Rico/Sanofi-

Synthelabo
 Puerto
Rico
	  		  	
	1682	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL PUERTO RICO
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	AUSTRALIA	  		  		  		  		  		  		  		  	 Bristol-Myers
 Squibb
 Australia

Pty. Ltd
	  		  	
	1741	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL AUSTRLIA
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

																					
	SPAIN	  		  		  		  		  		  		  		  	 Bristol-Myers Squibb, S.A.U.
	  		  	
	1395	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL SPAIN
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	GREECE	  		  		  		  		  		  		  		  	 Bristol-Myers Squibb A.E.
	  		  	
	1597	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL GREECE
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	GERMANY	  		  		  		  		  		  		  		  	 Bristol-Myers Squibb GmbH & Co.

 
 KGaA
	  		  	
	1332	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	 TOTAL GERMANY
	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

	ITALY	  		  		  		  		  		  		  		  	 Bristol-Myers Squibb S.r.l.
	  		  	
	1340	  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  		  		  		  		  		  		  	  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

		  	TOTAL ITALY	  		  		  		  		  		  		  		  		  	
		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  
	  	  

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 PART B 
  

									
	 Countries
Products
	  	 Products
	  	 SKU
	  	 Selling
Companies
	  	 Purchasing Companies

	 Austria
	  	Clopidogrel	  		  		  	
		  		  		  		  	
	 Belgium
	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  	Irbesartan	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	 Denmark
	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
	 Finland
	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
	 France
	  	Clopidogrel	  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

									
	 Countries
Products
	  	 Products
	  	 SKU
	  	 Selling
Companies
	  	Purchasing Companies
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  	Irbesartan	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	 Hong Kong
	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
	 Ireland
	  	Clopidogrel	  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

									
	 Countries

Products
	  	 Products
	  	 SKU
	  	 Selling
Companies
	  	Purchasing Companies
		  		  		  		  	
		  		  		  		  	
		  	Irbesartan	  		  		  	
	Italy	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	The Netherlands	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  	Irbesartan	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	Norway/Iceland	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	Portugal	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  	Irbesartan	  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

									
	 Countries
Products
	  	 Products
	  	 SKU
	  	 Selling
Companies
	  	Purchasing Companies
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	Sweden	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	Switzerland	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  	Irbesartan	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

									
	 Countries
Products
	  	 Products
	  	 SKU
	  	 Selling
Companies
	  	Purchasing Companies
		  		  		  		  	
	United Kingdom	  	Clopidogrel	  		  		  	
		  		  		  		  	
		  	Irbesartan	  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 4.2(b) 

ASSIGNED CONTRACTS 
  

	1.	Contracts with [*]. 

  

	 	a)	Agreement effective April 1, 2009 between [*] and [*]. 

  

	 	b)	Amending Agreement No. 1 effective as of July 15, 2010 between [*] and [*] 

 

	 	c)	Amending Agreement No. 2 effective as of April 26, 2011 between [*] and [*]. 

 

	2.	Additional [*] contracts. 

  

	 	a)	Industry Support Agreement effective as of November 18, 2010 among [*], [*] and [*]. 

 

	 	b)	Confidential Disclosure Agreement dated as of October 8, 2010 among [*], and [*]. 

 

	 	c)	Confidential Disclosure Agreement dated as of March 23, 2011 between [*] and [*]. 

 

	 	d)	Professional Services Agreement dated March 15, 2012, between [*] and [*] (each, a duly authorized representative of the [*] of the first part, and [*] of the
second part. 

  

	 	e)	Non-Disclosure Agreement dated as of February 8, 2012 between [*] and [*]. 

 

	 	f)	Confidential Disclosure Agreement dated as of July 12, 2011 between [*] and [*]. 

 

	 	g)	Confidential Disclosure Agreement dated as of February 14, 2012 between [*] and [*]. 

 

	 	h)	Confidential Disclosure Agreement dated as of March 1, 2011 between [*] and [*]. 

 

	 	i)	Professional Services Agreement dated as of January 10, 2012 between [*] and [*]. 

 

	 	j)	Confidential Disclosure Agreement dated as of December 22, 2011 between [*] and [*]. 

 

	 	k)	Professional Services Agreement effective as of May 10, 2012 between [*] and [*]. 

 

	 	l)	Convention de Non-Divulgation de Renseignements Confidentiels effective as of February 28, 2012 between [*] and [*] 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 7.2(b) 

INTELLECTUAL PROPERTY ACTIONS 
 [*] [NOTE: TABLE CONTENT IS OMITTED] 
 Clopidogrel 

 

									
	 Type of
Action
Brought
	  	 Country/
 Jurisdiction/

Court
	  	 Parties
	  	 Patents and Expiration

Dates, Including
 Extensions (in each
 case, if
applicable)
	  	 Date
 Suit

Filed

		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Irbesartan 
  

									
	 Type of
Action
Brought
	  	 Country/
 Jurisdiction/

Court
	  	 Parties
	  	 Patents and Expiration

Dates, Including
 Extensions (in each
 case, if
applicable)
	  	 Date
 Suit

Filed

		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 9.1 
 PENDING CLAIMS 
 [*] [NOTE: TABLE CONTENT IS OMITTED] 

Claims set forth on Schedule 7.2(b) are incorporated by reference in all instances where either Sanofi or BMS or their respective Affiliates (including
the alliance partnerships) face actual or threatened liability. 
 Clopidogrel 

 

									
	 Type of
Action
Brought
	  	 Country/
 Jurisdiction/

Court
	  	 Parties
	  	 Description
	  	 Date
 Suit

Filed

		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Irbesartan 
  

									
	 Type of
Action
Brought
	  	 Country/
 Jurisdiction/

Court
	  	 Parties
	  	 Description
	  	 Date
 Suit

Filed

		  		  		  		  	
		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Exhibit A 

Transfer of Marketing Authorizations 
 [*] [NOTE: TABLE CONTENT IS OMITTED] 
 MAs to be transferred to Sanofi 

The following information represents the best knowledge and intentions of the Parties as of the date of the side letter and is subject to change based on
interactions and feedback from regulators. 
 There are no ongoing regulatory procedures that impact the proposed submission dates and there are
no clinical trials being conducted for the MAs described below. 
 The ownership of the Irbesartan and Irbesartan hydrochlorotiazide Company
Core Data Sheets will be transferred to Sanofi at the time the E2B files and Excel sheets from BMS are imported into the Sanofi’s Pharmacovigilance database (AWARE) or at the time the approval of the last MAH transfer is approved Worlwide,
whichever comes first. 
  

																					
	 Country
	  	 Product
name
	  	 MA number
(s)
	  	 License
type
	  	 General description of HA

transfer process
	  	 Fees
(USD)
	  	 BMS obligations
	  	 Sanofi obligations
	  	 Expected
submission
date
	  	 Expected
approval
date
	  	 Comments

		  		  		  		  		  		  		  		  		  		  	

  
  
  

 
  
  

 
  

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 MAs to be withdrawn by BMS 

 

											
	 Country
	  	 Product

name
	  	 MA number (s)
	  	 License

type
	  	 Actual
Submission date
	  	 Approval date
 Actual (A)
 Expected
(E)

		  		  		  		  		  	
		  		  		  		  		  	
		  		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Cease of BMS as Sanofi’s regulatory agent 

 

															
	 Country
	  	 Product

name
	  	 MA
 number
 (s)
	  	 License

type
	  	 BMS obligations
	  	 Sanofi obligations
	  	 Expected
submission

date
	  	 Expected
effective

date

		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Exhibit B 

Swiss Share Purchase Agreement 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 EXECUTION VERSION 

TRANSFER OF SHARE AGREEMENT 
 AMONG 
 SANOFI SA, a company registered under Swiss law, having its head office at 3 route
de Montfleury, 1214 Vernier, Switzerland, 
 (hereinafter referred to as “SASA”), 

and 
 BRISTOL-MYERS SQUIBB AG, a company
registered under Swiss law, having its head office at Neuhodstrasse 6, 6340 Baar, Swizerland, 
 (hereinafter referred to as “BMS
AG”), 
 SASA and BMS AG shall also be hereinafter referred to as “Party” or collectively as the “Parties”, as the case
may be. 
 WITNESSETH 
 WHEREAS, on September 27, 2012 Sanofi entered into a Master Restructuring Agreement with Bristol-Myers Squibb to simplify the overall governance, operating and financial principles of its
alliance with respect to Ibersartan products worldwide (other than Japan, which is not cover by its alliance) and Clopidogrel products worldwide (other than in Japan, which is not covered by its alliance, and the U.S.); 

WHEREAS, in Switzerland the owner of the marketing authorizations of Irbesartan products and Clopidogrel products is the company
SANOFI/BRISTOL-MYERS SQUIBB SA (hereinafter referred to as SANOFI/BMS), which its head office at 3route de Montfleury, 1214 Vernier Switzerland; 
 WHEREAS, SANOFI/BMS is owned by SASA for [*] and BMS AG for [*]; 
 WHEREAS,
according to the Master Restructuring Agreement, at the closing date on January 1, 2013, SANOFI/BMS shall be owned at 100% by SASA; 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 NOW THEREFORE, in consideration of the mutual agreements and undertakings contained herein, the
Parties, intending to be legally bound hereby, agree as follows; 
 ARTICLE 1 
 BMS AG shall transfer to SASA [*] of SANOFI/BMS. Each share has a face value of [*]. 
 ARTICLE
2 
 The price of the transaction is [*]. The payment shall be done on January 1, 2013. 

ARTICLE 3 
 The transfer of the property
rights shall be effective on January 1, 2013. 
 ARTICLE 4 
 BMS AG confirms and guarantees that the [*] have no pledge, no mortgage or any other obligation, which can prevent the transfer, annihilate or reduce the rights of BMS AG on the [*]. 

ARTICLE 5 
 On January 1, 2013, [*]
shall resign of the board of Directors of SANOFI/BMS with immediate effect. 
 ARTICLE 6 

All disputes arising out of or in connection with this agreement shall be settled by the competent court in Geneva, Switzerland, in accordance with Swiss
Law. 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 IN WITNESS WHEREOF, the Parties hereto have caused this agreement to be executed by their duly
authorized representatives as of the date first above written. 
  

									
	Vernier,	 	  
	 		 		 	
	  
 SANOFI SA
	 		 	  
 BRISTOL-MYERS SQUIBB AG

					
	By:	 	  
	 		 	By:	 	  

	Name:	 	Fabrizio Guidi	 		 	Name:	 	
	Title:	 	Country Manager	 		 	Title:	 	
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	Robert-Henri Séchaud,	 		 	Name:	 	
	Title:	 	Licence Manager	 		 	Title:	 	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Exhibit C 
 [*] [NOTE: CONTENT IS OMITTED] 
 Return Process Proposal for Canada 

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 Exhibit D 

List of Tender Offers in Italy and Mexico to be assigned by BMS Affiliates to Sanofi Affiliates 

[*] [NOTE: TABLE CONTENT IS OMITTED] 

List of Tenders in Italy 
  

																					
	 Customer name
	  	Type of tender	  	Entry date	  	Tender
n.	  	Product	  	Q.ty	  	Last
price	  	disc.
%	  	start
from	  	end to	  	decision n.
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 List of Tenders in Mexico 

 

							
	 Institution
	  	 Product
	  	 Units in 2013
	  	 End Date

		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	

  

	*	CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONEX-10.q

 Exhibit 10q 
 *Confidential Treatment Requested 
 This text is a free
translation from the French language and is supplied solely for information purposes. 
 Only the original version in the
French language has legal force. 
 SANOFI PHARMA BRISTOL-MYERS SQUIBB 

General partnership with a capital of 
 Euro 50.000 
 Head office: 54 La Boétie street 75008 Paris France

 Trade and Companies Register of Paris 408 017 929 

ARTICLES OF ASSOCIATION 
 January 1, 2013 
 *CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1
 FORM OF ORGANIZATION
	  			
			
		 		  	 	5	  
		
	 ARTICLE 2
 COMPANY NAME
	  			
			
		 		  	 	5	  
		
	 ARTICLE 3
 COMPANY PURPOSE
	  			
			
		 		  	 	5	  
		
	 ARTICLE 4
 HEAD OFFICE
	  			
			
		 		  	 	6	  
		
	 ARTICLE 5
 DURATION
	  			
			
		 		  	 	6	  
		
	 ARTICLE 6
 DEFINITIONS
	  			
			
	 ARTICLE 6.1
	 	Defined Terms	  	 	6	  
	 ARTICLE 6.2
	 	Additional Defined Terms	  	 	7	  
		
	 ARTICLE 7
 CONTRIBUTIONS - SHAREHOLDINGS
	  			
			
	 ARTICLE 7.1
	 	Initial Contributions to the Share Capital	  	 	7	  
	 ARTICLE 7.2
	 	Shareholdings; Share Capital	  	 	7	  
	 ARTICLE 7.3
	 	Share Capital Increase	  	 	8	  
	 ARTICLE 7.4
	 	Share Capital Decrease	  	 	8	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

2 

							
	 ARTICLE 8
 REPRESENTATION OF SHARES – INDIVISIBILITY – RIGHTS AND
OBLIGATIONS OF
 THE PARTNERS
	  			
			
	 ARTICLE 8.1
	 	Representation of Shares	  	 	8	  
	 ARTICLE 8.2
	 	Indivisibility of Shares	  	 	8	  
	 ARTICLE 8.3
	 	Rights and Obligations of the Partners	  	 	8	  
		
	 ARTICLE 9
 DISTRIBUTION TO PARTNERS
	  			
		  	 	8	  
		
	 ARTICLE 10
 ACCOUNTING – STATUTORY AUDITORS – CORPORATE FINANCIAL

STATEMENTS – APPROVAL OF ANNUAL ACCOUNTS
	  			
			
	 ARTICLE 10.1
	 	Books and Records	  	 	8	  
	 ARTICLE 10.2
	 	Place and Right of Inspection	  	 	9	  
	 ARTICLE 10.3
	 	Fiscal Year	  	 	9	  
	 ARTICLE 10.4
	 	Statutory Auditor	  	 	9	  
	 ARTICLE 10.5
	 	Financial Statements	  	 	9	  
	 ARTICLE 10.6
	 	Bank Accounts	  	 	9	  
		
	 ARTICLE 11
 COMPANY MANAGEMENT
	  			
		  	 	9	  
		
	 ARTICLE 12
 DECISIONS OF PARTNERS
	  			
			
	 ARTICLE 12.1
	 	General Assembly and Written Consultation	  	 	10	  
	 ARTICLE 12.2
	 	Majority	  	 	10	  
	 ARTICLE 12.3
	 	Unanimity	  	 	10	  
	 ARTICLE 12.4
	 	Convening of the General Assembly	  	 	11	  
	 ARTICLE 12.5
	 	Written Consultation	  	 	11	  
		
	 ARTICLE 13
 TRANSFER OF SHARES
	  			
			
	 ARTICLE 13.1
	 	Absence of Transfer	  	 	11	  
	 ARTICLE 13.2
	 	New Partners	  	 	11	  
	 ARTICLE 13.3
	 	Effective Date of Transfer	  	 	12	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

3 

							
		 	 ARTICLE 14
 DISSOLUTION
	  			
			
	 ARTICLE 14.1
	 	Dissolution	  	 	12	  
	 ARTICLE 14.2
	 	Effect of Dissolution	  	 	12	  
	ARTICLE 14.3 Liquidation provisions	  	 	12	  
			
		 	 ARTICLE 15
 MISCELLANEOUS
	  			
			
	 ARTICLE 15.1
	 	Fiscal Regime	  	 	12	  
	 ARTICLE 15.2
	 	Litigations	  	 	12	  
	 ARTICLE 15.3
	 	Publications	  	 	13	  
	 ARTICLE 15.4
	 	Internal Rules	  	 	13	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

4 

 BETWEEN THE UNDERSIGNED: 
 1. Sanofi Participations, a single-shareholder simplified stock company with a capital of Euro 40.000, having its head office at 54 La Boétie street 75008 Paris, France, registered with the Trade
and Companies Register of Paris under number 407 571 728 (“Sanofi Partner”), a subsidiary indirectly and entirely held by Sanofi, a limited company with a capital of Euro 2.681.837.622, having its head office at 54 La Boétie
street 75008 Paris, France, registered with the Trade and Companies Register of Paris under number 395 030 844 (“Sanofi”), and 

2. BMS Investco SAS, a simplified stock company with a capital of Euro 40.000, having its head office at 3, Joseph Monier street, 92500 Rueil Malmaison,
registered with the Trade and Companies Register of Nanterre under number 407 846 195 (“BMS Partner”), a subsidiary directly and indirectly entirely held by Bristol-Myers Squibb Company, registered in Delaware (United States of
America), having its head office at 345 Park Avenue, New York, NY 10154 (“BMS”). 
 ARTICLE 1 – FORM OF ORGANIZATION

 The Partners have set a general partnership (the “Company”), governed by the Articles of Association and the Uniform
Commercial Code, and by any other legal provisions or regulations in force. The Company’s form can be changed by a decision of the Partners, made by a majority of votes according to the requirements of Article 12.3 of these Articles of
Association, provided that such modification does not incur the establishment of a new legal entity. 
 ARTICLE 2 – COMPANY
NAME 
 The Company name is SANOFI PHARMA BRISTOL-MYERS SQUIBB. The name shall be preceded or immediately followed by the words
société en nom collectif (“general partnership”) or by the initials “SNC” in all the deeds and documents issued by the Company for third parties. The activity of the Company can be managed, in accordance with
the legal provisions in force, under any other name established by the collective decision of the Partners, by a majority of votes, according to the requirements of Article 12.3 of these Articles of Association. 

ARTICLE 3 – COMPANY PURPOSE 

The Company shall have as purpose, directly or indirectly, and by any means, particularly by way of leasing its business, license or sublicense of all or
part of the intellectual property rights which it holds or benefits from, (a) to perform any activity related to the development, manufacturing and marketing of Products in Territory A and (b) to conclude, take over and execute all
contracts (business lease management contracts included) and other commitments and to undertake any activity that may be required or appropriate for the company purpose. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

5 

 ARTICLE 4 – HEAD OFFICE 
 The Company’s head office is located at 54 La Boétie street 75008 Paris, France. The head office can be transferred to another place in the same county or a bordering county by a simple
decision of the Manager(s), provided however that the head office cannot be transferred to any other place without the unanimous agreement of the Partners. 
 ARTICLE 5 – DURATION 
 The duration of the Company has been established to 99
years starting June 6, 1997, unless the Partners decide on the anticipated dissolution or extension 24 months at the latest prior to its termination. 
 ARTICLE 6 – DEFINITIONS 
  

	6.1	Defined Terms. When used in the Articles of Association, the following terms shall have the meanings below: 

“Partners” indicates Sanofi Partner and BMS Partner and each of their successors and beneficiaries; being however understood that any
Partner without shareholdings shall be considered as retired from the position as Partner of the Company. 
 “Clopidogrel”
indicates the chemical molecule discovered and patented by Sanofi and known under the SR 25990C code, and whose unregistered international name is Clopidogrel Hydrogenosulphate. 
 “Irbesartan” indicates the chemical molecule discovered and patented by Sanofi known under the SR 47436 code, and whose unregistered international name is Irbesartan. 

“Person” indicates any individual, partnership, company, including limited company, general partnership, joint venture company,
simplified stock company, joint-venture, association, trust or any other entity or administration or governmental agency or their subdivisions as well as any union or group considered to be a person according to Section 13(d) of US Securities
and Exchange Act of 1934 modified. 
 “Product” indicates a Clopidogrel Product or an Irbesartan Product and
“Products” indicates a Clopidogrel Product and an Irbesartan Product. 
 “Clopidogrel
Product” indicates (i) a product having Clopidogrel as sole active ingredient, in its finished form, marketed under Plavix® and Iscover® trademarks or
any other trademark whose similarity may generate confusion or which replaces one of them or (ii) a product (a “FDC Clopi Identifié”) containing as sole active ingredients a combination of Clopidogrel and acetylsalicylic
acid, in finished form, traded under Duoplavin®, CoPlavix® and DuoCover® trademarks or
any other trademark whose similarity may generate confusion or which replaces one of them. The term Clopidogrel Product excludes any other fixed-dose combination containing Clopidogrel. 

“Irbesartan Product” indicates (i) a product having Irbesartan as sole active ingredient, in its finished
form, marketed under Aprovel®, Karvea® and Avapro® trademarks or any
other trademark whose similarity may generate confusion or which replaces one of them or (ii) a product (a “FDC Irbe Identifié”) containing as sole active ingredients a combination of Irbesartan and Hydrochlorothiazide,
in finished form, traded under CoAprovel®, Avalide® and Karvezide® trademarks or
any other trademark whose similarity may generate confusion or which replaces one of them. The term Irbesartan Product excludes any other fixed-dose combination containing Irbesartan. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

6 

 “Affiliated Company”, in reference to a Person, indicates any other Person controlling,
controlled by, or under the joint control with, this Person; with specific understanding that, as regards Sanofi, the definition of Affiliated Company excludes L’Oréal. For the purpose of this definition, “control”
indicates (a) the direct or indirect power to influence or orientate the management of a Person or to veto any significant decision related to the management of a Person, in each of these cases either by holding of securities or shares with
right of vote, by contract or by any other means, (b) the direct or indirect holding of shares (excluding shares in a private company) representing at least 50% of the voting rights of a Person or (c) holding at least 50% of the shares of
a private company. 
 “Articles of Association” indicates these articles of association, modified, as the case may be.

 “Territory A” indicates the countries and geographical areas described in Appendix 1.1 enclosed hereof. 

 

	6.2	Additional Defined Terms. The following additional defined terms shall have the meaning stipulated by the articles listed below: 

 

			
	 Defined Terms
	  	Definition Article
	 Partners’ Assembly

General Assembly
 BMS Partner
 Sanofi Partner

BMS
 CCI
 Dispute

Fiscal Year
 Manager/Managers
 Dispute Notification

Sanofi
 Company
 Transfer
	  	10.5
 12.1
 Introduction
 Introduction
 Introduction
 15.2
 15.2
 10.3
 11(a)
 15.2
 Introduction
 1
 13.1

 ARTICLE 7 – CONTRIBUTIONS – SHAREHOLDINGS 

 

	7.1	Initial Contributions to the Share Capital. Upon the registration of the Company, dated July 10, 1996, BMS Partner and Sanofi Partner subscribed a
contribution in cash, i.e. Franc 24.950 and Franc 25.050. 

  

	7.2	Shareholdings. Share Capital. The shareholding of Sanofi Partner is 50.1% and the shareholding of BMS Partner is 49.9%. As a result of the aforementioned
contributions and following the conversion of the Share Capital in Euros, the Company’s Share Capital amounts to Euro 50.000, allocated to each Partner according to their shareholding. It is divided into 50.000 nominal shares in amount of Euro
1 allocated to each Partner according to their contribution, namely: 

 - 25.050 shares for Sanofi
Partner, 
 - 24.950 shares for BMS Partner. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

7 

	7.3	Share Capital Increase. The Share Capital can be increased by a collective decision of the Partners made within the general assembly of the Partners by a
majority of votes according to the requirements of Article 12.3 of these Articles of Association following the proposal of the Manager(s). 

  

	7.4	Share Capital Decrease. The Share Capital can be decreased for any reason whatsoever, by any means, particularly by way of proportional share buyback, by
way of decrease of their amount or number, by a collective decision of the Partners made within the general assembly of the Partners or by a majority of votes according to the requirements of Article 12.3 of these Articles of Association.

 ARTICLE 8 – REPRESENTATION OF SHARES – INDIVISIBILITY – RIGHTS AND OBLIGATIONS OF THE PARTNERS

  

	8.1	Representation of Shares. The shares cannot be represented by negotiable securities. 

 

	8.2	Indivisibility of Shares. Concerning the Company, the shares are indivisible, as it only has a single holder for each of them. 

 

	8.3	Rights and Obligations of the Partners. Each Partner has a right to the Company’s profits and any of its assets, proportional to its number of shares
in the Company. Each Partner is indefinitely and jointly liable for social security taxes. With respect to the relations between them, each of the Partners shall only be liable for social security taxes in proportion to the number of shares held.

 ARTICLE 9 – DISTRIBUTION TO PARTNERS 
 According to the majority requirements of Article 12.2 of these Articles of Association and following the proposal of the Manager(s), the Partners can distribute the distributable profit and decide on the
distribution of the amounts from the reserves which they have access to according to this document. 
 The Manager(s) can also decide on the
distribution of one or several interim dividends in accordance with the requirements stipulated by the Uniform Commercial Code. 
 The amounts
whose distribution is decided on shall be allocated to the Partners in proportion to the number of shares held by each of partner. 

ARTICLE 10 - ACCOUNTING – STATUTORY AUDITORS – CORPORATE FINANCIAL STATEMENTS – APPROVAL OF ANNUAL ACCOUNTS 

 

	10.1	 Books and Records. At any moment for the duration of the articles of association herein, at the expense of the Company, the Manager(s)
shall keep accounting books 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

8 

 
and records reflecting exactly and accurately, with a reasonable amount of details, all the Company related issues, including, without limitation, all its revenues, expenses, assets and
liabilities and (ii) a proper accounting internal management system. The Company’s accounts shall be kept according to the French accounting regulations. The Company shall not be bound to keep its accounts for a period exceeding ten years
(except for the records which must be kept for a longer period as required by law in the applicable country). 
  

	10.2	Place and Right of Inspection. The Company’s accounting books and records shall be kept and preserved at any moment in France in one or several
places approved by the Manager(s). This includes backed up duplicate data being held at off-site locations. Each Partner and its authorized representatives shall have the right to inspect, review, copy and audit the books, records, files, securities
and other documents of the Company at any time as and whenever necessary, for any purpose reasonably related to the shareholding of this Partner. The Company shall not charge any fees to a Partner for any inspection, review, copy or audit, other
than the current costs incurred by the Company. 

  

	10.3	 Fiscal Year. The Company’s Fiscal Year (the “Fiscal Year”) shall begin January 1st and shall end December 31st of each year. 

 

	10.4	Statutory Auditors. The Partners can or must, if compelled by law, according to the majority requirements of Article 12.2 of the Articles of Association,
appoint one or several statutory auditors of one or several internationally renowned accounting companies selected by the Manager(s). Each Statutory Auditor shall be appointed for a period of six (6) Fiscal Years expiring at the closing of the
assembly of Partners held for the review of the accounts of the sixth Fiscal Year. 

  

	10.5	Financial Statements. The Manager(s) shall prepare, according to the laws and regulations in force, an inventory as well as the financial statements of
the Company (balance sheet, profit and loss account and appendix) and a written management report which shall be submitted for the approval of the assembly of Partners within the six (6) months following the closing of each Fiscal Year
(“Assembly of Partners”). The financial statements, the management report and, as the case may be, the report of statutory auditors, the text of the resolutions submitted to the Assembly of Partners shall be provided to the Partners
at least fifteen (15) days prior to the Assembly of Partners. During the same period, the inventory shall be available for Partners at the Company’s head office. 

 

	10.6	Bank Accounts. The Company’s funds shall be deposited into an account or accounts in one or several French banking institutions chosen by the
Manager(s). 

 ARTICLE 11 – COMPANY MANAGEMENT 

 

	 	(a)  	 The Company shall be managed and administered by one or several Managers appointed by the Partners, according to the majority requirements of Article
12.2 of the Articles of Association, from among the candidates designated by Sanofi Partner and chosen from among the Affiliated Companies of Sanofi and, as for the pharmacist

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

9 

 
Manager in charge solely from among the employees and/or corporate officers of Sanofi. The terms “Manager” and “Managers,” as used in these articles of
association, shall indicate the individuals and legal entities, as the case may be, Partners or not, appointed according to Article 11.a) hereof. 
  

	 	(b)  	If the Company’s activities require the appointment of a pharmacist in charge, the Partners shall designate, by simple majority of shares, a Manager, or natural
person, who shall be the pharmacist in charge of the Company and who shall only have the powers required for making decisions basically allowing the compliance with the regulations in force. 

 

	 	(c)  	The Manager(s) shall be liable for the daily management of the Company. With respect to the relations with third parties, the Manager(s) shall have the power to draw up
any management documents included in the Company purpose, as defined by Article 3 hereof. 

  

	 	(d)  	Each Manager shall be appointed for a one year term renewable by the decision of Partners according to the majority requirements stipulated by Article 12.2 of the
Articles of Association. 

  

	 	(e)  	The Manager(s) shall be revocable by the collective decision of Partners made according to the majority requirements stipulated by Article 12.2 of the Articles of
Association. The revocation or resignation of a Manager shall not result in the Company’s dissolution. 

 ARTICLE 12
– DECISIONS OF PARTNERS 
  

	12.1	General Assembly – written consultation. The Partners’ will shall be expressed at the choice of the management, either within the general
assembly (hereinafter referred to as the “General Assembly”) or by means of written consultation. However, the convening of a General Assembly is mandatory (i) if the decisions concerned must be made within the general assembly
according to the law (and particularly the decisions regarding the annual approval of accounts) or to the express provisions of these Articles of Association or (ii) if a Partner requests the convening of a general assembly.

  

	12.2	Majority. Notwithstanding the decisions stipulated by Article 12.3 of the Articles of Association, the decisions submitted to the Partners shall be
validly adopted by one or several Partners representing more than half of the Company’s existing shares. 

  

	12.3	Unanimity. The following decisions shall be made by the Partners acting unanimously: 

 

	 	(a)	Any modification of the Articles of Association, including any change of the Company’s form of organization as well as any decision for the increase of the share
capital according to Article 7.3 of the Articles of Association; 

  

	 	(b)	The Company’s dissolution or liquidation; 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

10 

	 	(c)	The decisions for which legal or statutory provisions applicable to the Company require the unanimous consent of Partners; 

 

	 	(d)	Any decision to conclude any agreement (including any transaction within a litigation) involving one or several actual or potential payments to be made by the Company
higher than [*] cumulatively; 

  

	 	(e)	Any decision to conclude a transaction within a litigation by way of which the Company admits having committed an error. 

 

	12.4	Convening of the General Assembly. The General Assembly shall be convened by the Manager(s) through a registered letter with acknowledgement of receipt,
sent to the Partners at least fifteen (15) working days prior to the meeting and containing indications for the day, time, and place, as well as the agenda of the meeting. It can be convened by any Partner in the same conditions. It shall be
validly and immediately convened upon a verbal notice to attend, provided that all the Partners are present or statutorily represented. The General Assembly shall be chaired by the Manager or, in his/her absence, by the Partner convening the
meeting. 

  

	12.5	Written consultation. If the Manager(s) decides/decide to consult the Partners in writing, should such option be open, he (she)/they shall provide them
with the text of the resolutions submitted for their approval, together with all the documents and reports required for their information as well as a bulletin allowing them to express their vote for each resolution proposed. The Statutory Auditor
shall also be informed of this action. The deadline provided to Partners for returning this bulletin to the Company by registered letter with acknowledgement of receipt shall be fifteen (15) working days as of the sending date of the
consultation. The vote shall be expressed by yes or no by the partners. Any partner who has not responded within the deadline shall be considered as having voted “no” for purposes of this section. 

ARTICLE 13 – TRANSFER OF SHARES 
  

	13.1	Absence of Transfer. No share of the Company shall be sold, assigned, transferred, pledged or encumbered, entirely or partially, directly or indirectly,
by operation of law or otherwise (including, but without being limited to, by merger or distribution) (such sale, assignment, transfer, pledge or guarantee hereinafter being referred to as “Transfer”), without the prior unanimous
agreement of the Partners (which shall not be unreasonably rejected). Unless otherwise agreed by the Partners, any Transfer of any shareholding in violation of Article 13 hereof shall be considered null and void. 

 

	13.2	New Partners. No Person shall become a Partner in the sense and for the purposes hereof, unless such Person is ready to expressly undertake and accept to
be bound by all the provisions of the Articles of Association. All the costs and expenses reasonably incurred by the Company and related to a Transfer and, as the case may be, to the admission of a Person as Partner according to the requirements
herein shall be paid by the assignor. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

11 

	13.3	Effective Date of Transfer. Any Transfer according to Article 13 hereof shall be made in writing and shall be binding on the Company only following its
notification to the latter or following its approval in a deed drawn by a notary in accordance with the requirements of article 1690 of the Civil Code, or upon the submission of an original copy of the assignment deed at the head office against the
delivery by the Manager(s) of a certification for such deposit. Such Transfer shall only be binding on third parties following the completion of these formalities and publication of this Transfer into the relevant Trade and Companies Register.

 ARTICLE 14 – DISSOLUTION 
  

	14.1	Dissolution. The Company shall be dissolved and its activity shall be liquidated in case of occurrence of any of the events below:

  

	 	(i)	The decision of Partners to dissolve the Company according to the majority requirements of Article 12.3; 

 

	 	(ii)	The expiry of the Company duration according to Article 5 hereof. 

  

	14.2	Effects of Dissolution. In all cases of dissolution of the Company, the Company’s activity shall be terminated and consequently the Company shall be
dissolved as soon as possible and the following operations shall be performed: 

  

	 	(a)	The liquidator appointed by Sanofi Partner shall draw up a report of the Company’s assets and liabilities remaining upon the dissolution date and a copy of this
report shall be provided to each Partner; 

  

	 	(b)	The net liquidation product, following the extinguishment of liabilities and social security taxes, shall be used to refund the current accounts of Partners, if any, as
well as the amount of the nominal value of their shares; and 

  

	 	(c)	The balance, if any, constituting the liquidation surplus, shall be distributed to the Partners in proportion to their number of shares in the Company and, if the
liquidation incurs losses, they shall be borne by the Partners in the same proportion. 

  

	14.3	Liquidation Provisions. Sanofi Partner shall appoint the liquidator. 

 ARTICLE 15 – MISCELLANEOUS 
  

	15.1	Fiscal Regime. The Company shall not opt for corporate tax liability. 

 

	15.2	 Litigations. These Articles of Association as well as related rights and obligations shall be governed by the French law. In case of
litigations, claims, disputes or disagreements (a “Dispute”) resulting from or related to these Articles of Association, including any issue regarding the validity, existence and termination of these Articles of Association, the
Partners shall first try to settle their Dispute by negotiation. This process of negotiation shall be considered open when one of the Partners sends a notification in writing (a “Notification of Dispute”) to the other Partner.
Should a Dispute submitted to the negotiation procedure, according to the aforementioned 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

12 

 
requirements, not be definitively settled within a period of 30 days as of the reception by one of the Partners of the Notification of Dispute, the Dispute shall be deferred to a mediation
procedure in accordance with the Mediation Regulations of the International Chamber of Commerce (the “CCI”). The mediation court shall be composed of three mediators. Each Partner shall appoint a mediator. The two mediators
appointed shall appoint the president of the mediation court. If one of the Partners does not appoint a mediator in the petition for mediation or within the 30 days upon the reception of a notification in writing stating the appointment of a
mediator by the other Partner, the aforementioned mediator shall be appointed by the CCI. Should the two mediators appointed by the Partners fail to reach an agreement on the appointment of a third mediator within a period of 30 days as of the
appointment of the second mediator, the third mediator shall be appointed by the CCI. The mediation procedure shall be held in Paris, France and the proceedings shall be conducted in English. Notwithstanding any contrary clause in the Mediation
Regulations of the International Chamber of Commerce, each Partner shall bear its own costs and charges related to the aforementioned mediation procedure and all related procedures, legal fees included. Each Partner shall continue to fulfill its
obligations according to the Articles of Association and the provisions of the Articles of Association shall be further applied until the settlement of this Dispute. 
  

	15.3	Publications. The Partners shall grant all powers to the holder of an original copy of these Articles of Association in order to perform all the publicity
formalities required. 

  

	15.4	Internal Regulations. The Articles of Association shall be completed and clarified by internal regulations which can only be modified by common consent of
the Partners. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

13 

 APPENDIX 1.1 
 TERRITORY A 
 Clopidogrel Product and Irbesartan product: 

 

	 	-	Germany, 

	 	-	Belgium, 

	 	-	Spain, 

	 	-	Greece, 

	 	-	Italy, 

	 	-	Netherlands, 

	 	-	Portugal, 

	 	-	Switzerland. 

 Clopidogrel Product only:

  

	 	-	Austria, 

	 	-	Cyprus, 

	 	-	South Korea, 

	 	-	Denmark, 

	 	-	Finland, 

	 	-	Hong-Kong, 

	 	-	Iceland, 

	 	-	Israel, 

	 	-	Ireland, 

	 	-	Norway, 

	 	-	Sweden, 

	 	-	Taiwan, 

	 	-	France (metropolitan). 

 For Irbesartan only:

  

	 	-	France (DOMTOM included) 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]